Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics (ALLO)
:ALLO
RESEARCH TOOLSreports
ALLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $5.15
Previous CloseN/A
Volume1.66M
Average Volume (3M)7.84M
Market Cap
$429.83M
Enterprise Value$386.69M
Total Cash (Recent Filing)$83.16M
Total Debt (Recent Filing)$95.12M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Mar 13, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding209,672,090
10 Day Avg. Volume3,508,316
30 Day Avg. Volume7,837,366
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4811.42
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.59
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$11.50Price Target Upside460.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Allogene Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Efficacy DataUpdated Phase I ALPHA/ALPHA 2 Data Supports Efficacy Profile of Cema-Cel.
Product InnovationAllogene's ALLO-329 avoids halting immunosuppression for several weeks before T-cell apheresis, because ALLO-329 is a ready-to-use product.
Bears Say
Program DiscontinuationThe discontinuation of the CLL program is seen as unfortunate due to slower-than-anticipated trial enrollment and the emergence of new alternative treatment options.
---
Ownership Overview
10.22% Insiders
25.78% Mutual Funds
<0.01% Other Institutional Investors
53.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics’s price range in the past 12 months?
Allogene Therapeutics lowest stock price was $1.32 and its highest was $5.15 in the past 12 months.
What is Allogene Therapeutics’s market cap?
Allogene Therapeutics’s market cap is $429.83M.
When is Allogene Therapeutics’s upcoming earnings report date?
Allogene Therapeutics’s upcoming earnings report date is Mar 13, 2025 which is tomorrow.
How were Allogene Therapeutics’s earnings last quarter?
Allogene Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.333 by $0.013.
Is Allogene Therapeutics overvalued?
According to Wall Street analysts Allogene Therapeutics’s price is currently Undervalued.
Does Allogene Therapeutics pay dividends?
Allogene Therapeutics does not currently pay dividends.
What is Allogene Therapeutics’s EPS estimate?
Allogene Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Allogene Therapeutics have?
Allogene Therapeutics has 209,672,090 shares outstanding.
What happened to Allogene Therapeutics’s price movement after its last earnings report?
Allogene Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.333. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of Allogene Therapeutics?
Currently, no hedge funds are holding shares in ALLO
---
Allogene Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (460.98% Upside)
$11.50 (460.98% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.02%
12-Months-Change
Fundamentals
Return on Equity
-54.15%
Trailing 12-Months
Asset Growth
-17.30%
Trailing 12-Months
Company Description
Allogene Therapeutics
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials for both cancer and autoimmune diseases, showing promising efficacy and strong financial positioning. However, concerns about safety profiles and delays in regimen finalization pose challenges.Read More>---
ALLO Stock 12 Month Forecast
Average Price Target
$11.50
▲(460.98% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-21.83%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.83% per trade.
---